Alnylam unveils pricing strategy for second FDA-approved RNAi drug

Alnylam unveiled a performance-based and prevalence-based pricing strategy to mitigate risks to participating payers covering RNAi therapy Givlaari givosiran, which FDA approved more than two months ahead of schedule for adults with acute hepatic porphyria.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) plans to launch

Read the full 412 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE